Thursday, November 1, 2012
Dynavax Technologies Corp., of Berkeley, Calif., said it will advance AZD1419, a second-generation Toll-like receptor 9 agonist for asthma, into Phase I studies.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.